101 related articles for article (PubMed ID: 17942927)
61. [Inhibitory Fc receptor].
Ono M
Seikagaku; 1999 Oct; 71(10):1227-31. PubMed ID: 10572480
[No Abstract] [Full Text] [Related]
62. Phosphatidylinositol-3 phosphatase myotubularin-related protein 6 negatively regulates CD4 T cells.
Srivastava S; Ko K; Choudhury P; Li Z; Johnson AK; Nadkarni V; Unutmaz D; Coetzee WA; Skolnik EY
Mol Cell Biol; 2006 Aug; 26(15):5595-602. PubMed ID: 16847315
[TBL] [Abstract][Full Text] [Related]
63. Ginsenoside Re enhances survival of human CD4+ T cells through regulation of autophagy.
Son YM; Kwak CW; Lee YJ; Yang DC; Park BC; Lee WK; Han SH; Yun CH
Int Immunopharmacol; 2010 May; 10(5):626-31. PubMed ID: 20230918
[TBL] [Abstract][Full Text] [Related]
64. Applications of multiparametric flow cytometry: providing new insights into biology to bridge the gap between research discovery and clinical application.
Cesano A; Parkinson D
Cytometry A; 2012 Sep; 81(9):732-3. PubMed ID: 22730060
[No Abstract] [Full Text] [Related]
65. Phosphatases in concert with kinases set the gain for signal transduction through the T cell receptor.
Schade AE; Levine AD
Mol Immunol; 2003 Dec; 40(8):531-7. PubMed ID: 14563372
[TBL] [Abstract][Full Text] [Related]
66. Immunointervention in psoriasis with anti-CD4 antibodies.
Thivolet J; Nicolas JF
Int J Dermatol; 1994 May; 33(5):327-32. PubMed ID: 7913701
[No Abstract] [Full Text] [Related]
67. Class I PI3K Provide Lipid Substrate in T Cell Autophagy Through Linked Activity of Inositol Phosphatases.
McLeod IX; Saxena R; Carico Z; He YW
Front Cell Dev Biol; 2021; 9():709398. PubMed ID: 34458267
[TBL] [Abstract][Full Text] [Related]
68. [Mechanism of Action of Vermin T 14].
KRANICH JW; NOCKER PA
Dtsch Tierarztl Wochenschr (1946); 1947 Jul; 54(25-26):185. PubMed ID: 20270548
[No Abstract] [Full Text] [Related]
69. Treatment of aggressive T-cell lymphoma/leukemia with anti-CD4 CAR T cells.
Feng J; Xu H; Cinquina A; Wu Z; Zhang W; Sun L; Chen Q; Tian L; Song L; Pinz KG; Wada M; Jiang X; Hanes WM; Ma Y; Zhang H
Front Immunol; 2022; 13():997482. PubMed ID: 36172388
[TBL] [Abstract][Full Text] [Related]
70. Enhancement of antitumor effect by peptide vaccine therapy in combination with anti-CD4 antibody: Study in a murine model.
Fujinami N; Yoshikawa T; Sawada Y; Shimomura M; Iwama T; Sugai S; Kitano S; Uemura Y; Nakatsura T
Biochem Biophys Rep; 2016 Mar; 5():482-491. PubMed ID: 28955856
[TBL] [Abstract][Full Text] [Related]
71. Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells.
Pinz K; Liu H; Golightly M; Jares A; Lan F; Zieve GW; Hagag N; Schuster M; Firor AE; Jiang X; Ma Y
Leukemia; 2016 Mar; 30(3):701-7. PubMed ID: 26526988
[TBL] [Abstract][Full Text] [Related]
72. Management of cutaneous T cell lymphoma: new and emerging targets and treatment options.
Li JY; Horwitz S; Moskowitz A; Myskowski PL; Pulitzer M; Querfeld C
Cancer Manag Res; 2012; 4():75-89. PubMed ID: 22457602
[TBL] [Abstract][Full Text] [Related]
73. Cutaneous T-cell lymphomas: a review of new discoveries and treatments.
Bloom T; Kuzel TM; Querfeld C; Guitart J; Rosen ST
Curr Treat Options Oncol; 2012 Mar; 13(1):102-21. PubMed ID: 22311555
[TBL] [Abstract][Full Text] [Related]
74. Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients.
Clark RA; Watanabe R; Teague JE; Schlapbach C; Tawa MC; Adams N; Dorosario AA; Chaney KS; Cutler CS; Leboeuf NR; Carter JB; Fisher DC; Kupper TS
Sci Transl Med; 2012 Jan; 4(117):117ra7. PubMed ID: 22261031
[TBL] [Abstract][Full Text] [Related]
75. Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
Wong HK; Mishra A; Hake T; Porcu P
Br J Haematol; 2011 Oct; 155(2):150-66. PubMed ID: 21883142
[TBL] [Abstract][Full Text] [Related]
76. Antibody-based therapeutics to watch in 2011.
Reichert JM
MAbs; 2011; 3(1):76-99. PubMed ID: 21051951
[TBL] [Abstract][Full Text] [Related]
77. New targets of therapy in T-cell lymphomas.
Erter J; Alinari L; Darabi K; Gurcan M; Garzon R; Marcucci G; Bechtel MA; Wong H; Porcu P
Curr Drug Targets; 2010 Apr; 11(4):482-93. PubMed ID: 20196721
[TBL] [Abstract][Full Text] [Related]
78. New insights into T cell biology and T cell-directed therapy for autoimmunity, inflammation, and immunosuppression.
Steward-Tharp SM; Song YJ; Siegel RM; O'Shea JJ
Ann N Y Acad Sci; 2010 Jan; 1183():123-48. PubMed ID: 20146712
[TBL] [Abstract][Full Text] [Related]
79. Partial CD4 depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy.
LaCelle MG; Jensen SM; Fox BA
Clin Cancer Res; 2009 Nov; 15(22):6881-90. PubMed ID: 19903784
[TBL] [Abstract][Full Text] [Related]
80. Antibody-based therapy of leukaemia.
Morris JC; Waldmann TA
Expert Rev Mol Med; 2009 Sep; 11():e29. PubMed ID: 19788782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
